my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
21-10-2010: The Max Planck Institute (MPI) of Biochemistry in Martinsried and pharmaceutical company GlaxoSmithKline GmbH & Co. KG (GSK) have signed a research agreement on the development of new drugs for the treatment of type II diabetes. The cooperation agreement, negotiated with the help of technology transfer organisation Max Planck Innovation, is worth several million euros and covers a three-year period.
The recently signed cooperation agreement between the MPI of Biochemistry and GSK pursues the objective of developing innovative new drugs. The joint research and development work is based on the research findings of Axel Ullrich, Director at the MPI of Biochemistry. He and fellow scientist Mathias Bäcker successfully described the role of certain protein molecules - known as kinases - in connection with the development of type II diabetes, a disease in which insulin resistance gives rise to a raised blood sugar level. These kinases make up a group of important signal molecules in the body, which can, under certain circumstances, be involved in the development or manifestation of the disease. In the collaborative project with GSK, the scientists are looking for new substances that can inhibit this kinase activity and control it in a targeted manner.
Axel Ullrich already achieved a milestone in the treatment of diabetes back in 1977, together with fellow scientists at the University of California. At that time, he developed a method of transferring a copy of the human insulin gene into bacteria. This facilitated the industrial manufacture of human insulin for the very first time and has since made it easier for millions of diabetics to live with the disease, as they no longer have to depend on animal insulin, which is not nearly so well tolerated by the human body.
Axel Ullrich’s current research is set to contribute to the successful treatment of diabetes a second time. "Developing innovative drugs to treat diabetes gives us the opportunity to directly influence defects in the molecular signal paths, which lie at the root of diabetes. That enables us to fight the actual causes of diabetes," says Ullrich. Peter Gruss, President of the Max Planck Society expressed his delight with the collaboration agreement: "GlaxoSmithKline is one of the world's five major pharmaceutical companies. The collaboration agreement with GSK testifies to the fact that Max Planck Institutes, due to their leading edge in basic research, are also sought-after partners in industry. Max Planck researchers generate ideas for new approaches in application-oriented industrial research. We hope that together with a strong partner, we will be able to translate research findings into therapies which will enhance patient quality of life."
Prof Ullrich’s longstanding expertise in molecular biology research is again being put to good use, having already resulted in some very successful therapeutic agents. For example, Herceptin®, a drug he developed, is successfully used to treat metastasised breast cancer. The drug Sutent®, which treats malignant tumours in the gastrointestinal tract (GIST) and renal cancer (MRCC) is also based on Ullrich’s research work. In the case of both of the above drugs, the suppression of certain kinase activity with suitable inhibitors is central to the treatment.
Watchlist
This is where you can add this news to your personal favourites
Priaxon enters collaboration with GSK on Protein-Protein-Interactions
Priaxon announced a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions. Priaxon will provide its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigating the modul ... more
Prosensa has selected clinical candidates for two more compounds for the treatment of Duchenne muscular dystrophy (DMD) and has been granted orphan drug designation for two additional DMD compounds in its pipeline.Prosensa identified suitable oligonucleotide candidates for PRO052 and PRO055 ... more
KineMed Announces Biomarker Discovery Collaboration with GSK
KineMed, Inc. announced a multi-year R&D collaboration with GlaxoSmithKline plc (GSK) that will apply KineMed’s proprietary biomarker discovery platform in therapeutic areas of interest to GSK. The collaboration will seek to identify, optimize and validate novel biomarkers that would enable ... more
The evolutionary consequences of infidelity
In the bird world, male and female blue tits are hard to distinguish for the human observer. However, in the UV-range, visible to birds, the male is much more colourful. A closer look at the monogamous mating system of these birds again reveals that all is not what it seems: in every second ... more
New citation indicators needed to measure research performance
How do you compare the impact of a researcher in chemistry or physics with a molecular biologist who may be working on similar projects? Two experts support the use of citation indicators that are based on percentiles, a statistical parameter that allows for comparisons with a carefully def ... more
A macromolecular shredder for RNA
Much in the same way as we use shredders to destroy documents that are no longer useful or that contain potentially damaging information, cells use molecular machines to degrade unwanted or defective macromolecules. Scientists of the MPI of Biochemistry have now decoded the structure and th ... more
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
The research institutes of the Max Planck Society perform basic research in the interest of the general public in the natural sciences, life sciences, social sciences, and the humanities. In particular, the Max Planck Society takes up new and innovative research areas that German universiti ... more
Anticancer substances clear next hurdle
Scientists of the MPI of Biochemistry and their cooperation partners of the Lead Discovery Center GmbH (LDC) have now signed a licensing agreement with the Korean company Qurient for a group of active substances that have been a focus of their research for a long time. These substances shal ... more
A macromolecular shredder for RNA
Much in the same way as we use shredders to destroy documents that are no longer useful or that contain potentially damaging information, cells use molecular machines to degrade unwanted or defective macromolecules. Scientists of the MPI of Biochemistry have now decoded the structure and th ... more
Proteins are the molecular building blocks and machinery of cells and involved in practically all biological processes. To fulfil their tasks, they need to be folded into a complicated three-dimensional structure. Scientists from the Max Planck Institute of Biochemistry (MPIB) in Martinsrie ... more
Drug Response Dx GmbH (DRDx GmbH) concluded its first round of financing with High-Tech Gründerfonds and QIAGEN. The investment will serve to develop a biomarker test kit for rheumatoid arthritis treatment guidance with so-called TNF-alpha inhibitors. The test is secured by a patent platfor ... more
The Lead Discovery Center GmbH (LDC), based in Dortmund, Germany, a spin-off from Max-Planck-Innovation GmbH (MI) in Munich, with expertise in small molecule pharmaceutical drug discovery, has successfully licensed its first lead structure to a pharma partner. The agreement grants Bayer Sch ... more
Cooperation in diabetes research
The Max Planck Institute (MPI) of Biochemistry in Martinsried and pharmaceutical company GlaxoSmithKline GmbH & Co. KG (GSK) have signed a research agreement on the development of new drugs for the treatment of type II diabetes. The cooperation agreement, negotiated with the help of technol ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
